Monitor upcoming catalysts: adult SR-aGvHD label expansion trial activation, DMD trial initiation, and CLBP Phase 3 data. Revenue trajectory and cash burn improvement support a positive outlook.
Price Chart
Executive Summary
Mesoblast reported Q3 FY2026 Ryoncil net revenues of US$30.3M and a reduced net operating cash spend of US$4.1M, with cash at US$122M. Operational highlights include completion of patient recruitment in the pivotal Phase 3 chronic low back pain trial and FDA clearance for label expansion trials in adult SR-aGvHD and Duchenne muscular dystrophy.
Key Facts
- Ryoncil net revenues of US$30.3M for Q3 FY2026 (gross sales US$35.3M)
- Net operating cash spend reduced to US$4.1M for the quarter
- Cash and cash equivalents of US$122M at March 31, 2026
- Patient recruitment target achieved in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain
- FDA cleared IND for registrational trial of Ryoncil in Duchenne muscular dystrophy
- Acquired exclusive worldwide license for CAR technology platform
Financial Impact
Ryoncil net revenue of US$30.3M, net operating cash spend reduced to US$4.1M, cash balance US$122M
Risk Factors
- Reliance on successful Ryoncil launch and market adoption
- Clinical trial risks for pipeline candidates
- Competitive landscape in cell therapy
- Ongoing negative operating cash flow despite improvement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000055 |
| Document: form6-kxpressreleasecoverf.htm | 0001345099-26-000055 |
| Document: 0001345099-26-000055-index-headers.html | 0001345099-26-000055 |
| Document: 0001345099-26-000055-index.html | 0001345099-26-000055 |
| Document: 0001345099-26-000055.txt | 0001345099-26-000055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $1.55 $1.55 | · 0.00% | ▼ −3.89% | $1.32 (−14.84%) |
Apr 30, 2026 25w ago | 6-K | $1.70 $1.70 | · 0.00% | ▼ −5.23% | $1.32 (−22.35%) |
Apr 16, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.32 (−17.50%) |
Apr 15, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers